Dividendos de Willow Biosciences

Dividendo controles de criterios 0/6

Willow Biosciences no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-CA$0.083
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

May 20

Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

Jan 19

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de WLLW han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de WLLW han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Willow Biosciences vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de WLLW con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (WLLW)	n/a
Suelo de mercado 25% (CA)	1.9%
Techo de mercado 25% (CA)	6.4%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (WLLW)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de WLLW en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de WLLW en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de WLLW para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que WLLW no ha comunicado ningún pago.

Dividendos de Willow Biosciences

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Willow Biosciences Inc., Annual General Meeting, Jul 26, 2024

Willow Biosciences Inc. announced that it expects to receive CAD 3 million in funding

New minor risk - Share price stability

New major risk - Financial position

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.12 loss in FY 2022)

New major risk - Market cap size

New minor risk - Shareholder dilution

Willow Biosciences Inc. announced that it expects to receive funding from Kalsec Inc.

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.032 loss in 3Q 2022)

Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences Inc

Aurora Cannabis Inc. Announces Settlement of Patent Litigation with Willow Biosciences Inc

Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding

Willow Biosciences Inc. announced that it has received CAD 0.8 million in funding

Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding

Willow Biosciences Inc. announced that it expects to receive CAD 1.2 million in funding

Willow Biosciences Inc. Announces Successful Completion of R&D Program on Covid

Willow Biosciences Inc. Announces Filing of Patent Application for Process to Produce Corticosteroids At Significantly Reduced Cost

Willow Biosciences Inc. Announces Board Changes

New major risk - Market cap size

Willow Biosciences Inc. Announces Executive Changes

Full year 2022 earnings released: CA$0.12 loss per share (vs CA$0.051 loss in FY 2021)

Willow Biosciences Inc. Provides Earnings Guidance for the Year 2023

Insufficient new directors

Third quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.031 profit in 3Q 2021)

Willow Biosciences Inc. Appoints Dr. Peter Seufer-Wasserthal as its CEO

Willow Biosciences Inc. Completes Proof of Concept Work and Starts Yeast Strain Optimization and Process Development Toward Commercial Production of Astaxanthin

Independent Director recently bought CA$63k worth of stock

Second quarter 2022 earnings released: CA$0.03 loss per share (vs CA$0.053 profit in 2Q 2021)

Willow Biosciences Inc. Appoints Dr. Peter Seufer-Wasserthal as Interim President

First quarter 2022 earnings released: CA$0.02 loss per share (vs CA$0.10 loss in 1Q 2021)

Insufficient new directors

Is Willow Biosciences (TSE:WLLW) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: CA$0.05 loss per share (vs CA$0.41 loss in FY 2020)

Willow Biosciences Inc. Announces Results of its in Vitro Analysis and First to Report Topical Clinical Study on Cannabigerol in Collaboration with Signum Biosciences

We Think Willow Biosciences (TSE:WLLW) Needs To Drive Business Growth Carefully

President recently bought CA$60k worth of stock

We Think Willow Biosciences (TSE:WLLW) Can Afford To Drive Business Growth

We Think Willow Biosciences (TSE:WLLW) Can Easily Afford To Drive Business Growth

First quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.018 loss in 1Q 2020)

Willow Biosciences Inc., Annual General Meeting, Apr 28, 2021

Independent Director exercised options to buy CA$187k worth of stock.

New 90-day high: CA$1.81

Willow Biosciences Inc. Advances its Work on Tetrahydrocannabinol and Plans to Launch in the Canadian Market

Calculating The Fair Value Of Willow Biosciences Inc. (TSE:WLLW)

Willow Biosciences Provides Update on Cannabigerol Research Studies

New 90-day high: CA$1.19

New 90-day high: CA$0.81

Willow Biosciences Advances Its Commericalization Plan

Willow Biosciences Inc. announced that it has received $1.168596 million in funding

President recently bought CA$192k worth of stock

Willow Biosciences Inc. has completed a Composite Units Offering in the amount of CAD 10 million.

New 90-day low: CA$0.55

Willow Biosciences Partners with Researchers At the University of Lethbridge and University of Calgary to Study Effects of Non-Psychoactive Cannabinoids on Pain, Inflammation and Depression

Willow Biosciences Inc. Announces Successful Production of Pure Cannabigerol

New 90-day high - CA$0.81

Earnings released

New 90-day high - CA$0.57

Willow Biosciences to Commence Trading on The OTCQX® Best Market

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos